Tecartus – pro
ecartus is FDA approved for adult patients with relapsed or refractory mantle cell lymphoma (MCL). Another Indication for relasped or refractory precursor acute lymphoblastic leukemia (ALL).
The ZUMA-2 trial evaluated Tecartus in patients with relapsed/refractory mantle cell lymphoma who received one to five prior lines of therapy including a BTK inhibitor. In the primary efficacy analysis (60 patients), the objective response rate was 93% and the complete response rate was 67% at a median follow-up of 12.3 months.
Objective response rate served as the major focus of the trial, with additional areas of focus including duration of response, progression-free survival (time during and after treatment when a patient lives with cancer without disease progression), overall survival (time from treatment initiation that a patient is still alive), side effects and levels of CAR-T cells in the blood and cytokines in serum. Updated results sowed that:
median duration of response, progression-free survival and overall survival had not been reached at the median follow-up.
ecartus is FDA approved for adult patients with relapsed or refractory mantle cell lymphoma (MCL). Another Indication for relasped or refractory precursor acute lymphoblastic leukemia (ALL).
The ZUMA-2 trial evaluated Tecartus in patients with relapsed/refractory mantle cell lymphoma who received one to five prior lines of therapy including a BTK inhibitor. In the primary efficacy analysis (60 patients), the objective response rate was 93% and the complete response rate was 67% at a median follow-up of 12.3 months.
Objective response rate served as the major focus of the trial, with additional areas of focus including duration of response, progression-free survival (time during and after treatment when a patient lives with cancer without disease progression), overall survival (time from treatment initiation that a patient is still alive), side effects and levels of CAR-T cells in the blood and cytokines in serum. Updated results sowed that:
median duration of response, progression-free survival and overall survival had not been reached at the median follow-up.